Intrauterine CRH‐treated PBMC in repeated implantation failure

Abstract

The intrauterine administration of activated autologous peripheral blood monocytes (PBMC) prior to embryo transfer seems to improve reproductive outcomes in women with repeated implantation failure (RIF). We have previously shown that the intrauterine administration of PBMC treated with corticotropin‐releasing hormone (CRH) prior to blastocyst transfer (day 5) improves significantly the clinical pregnancy rate of women with RIF. In the present crossover pilot study, we have investigated whether CRH‐PBMC treatment could be of benefit in case of fresh early cleavage stage embryo transfer (day 3) in women with RIF.